Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,084 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: HIV, Coronary Artery Disease
Interventions: metformin extended release; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 45 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Urinary Bladder, Overactive
Interventions: tolterodine extended release; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 96
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 83 more

Conditions: Psoriasis, Cardiovascular Disease
Interventions: Adalimumab; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 9
States / cities: Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more

Conditions: Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 15
States / cities: Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more

Conditions: Disorder of Knee
Interventions: Oxycodone; Drug
Lead sponsor: International Clinical Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions: SUSTOL; Drug
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Hattiesburg, Mississippi • Canton, Ohio

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin tartrate (ACP-103); Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 83
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: pirfenidone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: South San Francisco, California

Conditions: Colitis, Ulcerative
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 56
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more

Conditions: Connective Tissue Diseases
Interventions: Belimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Philadelphia, Pennsylvania

Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more

Conditions: Epilepsy
Interventions: lamotrigine extended-release; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 12
States / cities: Anniston, Alabama • Sun City, Arizona • Lexington, Kentucky + 8 more

Conditions: Multiple Sclerosis
Interventions: Fampridine-SR; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 91
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Dermatitis, Atopic
Interventions: Spesolimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more

Conditions: Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions: Paliperidone ER; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 14
States / cities: Cerritos, California • San Diego, California • Santa Ana, California + 11 more

Conditions: Parkinson's Disease With Motor Fluctuations
Interventions: 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751, 15 mg QD PF-06649751, 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study), 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 87 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 9
States / cities: Newport Beach, California • Fairfield, Connecticut • Boca Raton, Florida + 5 more

Conditions: Menorrhagia
Interventions: Tranexamic acid; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 92
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more

Conditions: Neuroendocrine Carcinoma
Interventions: Atiprimod; Drug
Lead sponsor: Callisto Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Little Rock, Arkansas • New York, New York

Conditions: Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions: Armodafinil 100 to 250 mg/day; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more

Conditions: Ulcerative Colitis
Interventions: PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD, Placebo, PF-6826647 400 mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Canoga Park, California • Inglewood, California • Newport Beach, California + 12 more

Conditions: Hereditary Angioedema (HAE)
Interventions: Deucrictibant; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 12 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more

Search by objective public record fields.

Metformin for HIV Inflammation

A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

Vascular Inflammation in Psoriasis - Extension Study

Dysport® Adult Lower Limb Spasticity Follow-on Study

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery

Safety Study of Repeat Doses of SUSTOL in Adults

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE